Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) is a clinical-stage biotherapeutics pioneer developing novel medicines for serious inflammatory, fibrotic, and immunological conditions. This news hub provides investors and industry professionals with centralized access to verified corporate announcements and scientific updates.
Track PRTC's progress through key developments including clinical trial milestones, regulatory submissions, and strategic partnerships. Our curated collection features official press releases on therapeutic advancements across the company's pipeline, particularly in gastrointestinal disorders, oncology, and neurological diseases.
Stay informed about PRTC's unique approach to modulating the adaptive human system through its Wholly-Owned Programs and Founded Entities structure. All content maintains strict editorial standards to ensure accuracy and compliance with financial disclosure regulations.
Bookmark this page for direct access to PureTech Health's latest verified updates, including research publications, patent filings, and partnership announcements. Check regularly for new developments in this innovative biopharma company's pursuit of transformative therapies.
PureTech (Nasdaq: PRTC) announced that Celea Therapeutics completed an End-of-Phase 2 meeting with the FDA for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF).
The FDA feedback supports advancing to a global pivotal Phase 3 SURPASS-IPF trial, planned to start in the first half of 2026, and indicates a streamlined 505(b)(2) pathway could be possible if a single Phase 3 is successful and supported by the totality of deupirfenidone data. Phase 3 will be a 52-week, randomized, double-blind head-to-head trial versus pirfenidone, with primary endpoint change in absolute FVC at week 52.
Phase 2b ELEVATE-IPF results cited: deupirfenidone 825 mg TID showed a 91 mL FVC advantage vs placebo at 26 weeks and a maintained -32.8 mL FVC decline over 52 weeks in extension. Celea expects to finalize financing in early 2026 to support Phase 3 initiation.
Gallop Oncology (Nasdaq:PRTC) announced initial topline Phase 1b results for LYT-200 in relapsed/refractory AML and high-risk MDS, showing a favorable safety profile and encouraging efficacy.
At the proposed Phase 2 dose (12 mg/kg) in combination with venetoclax/hypomethylating agent: 38% combined complete response, 97% disease control, and initial median overall survival of 13.2 months. Monotherapy median overall survival was 6.5 months. No LYT-200–related serious adverse events or dose‑limiting toxicities observed (n=101). Final overall survival data expected in 1H 2026; additional details to be presented at ASH 2025 on December 6, 2025.
PureTech (Nasdaq: PRTC) announced that Founded Entity Gallop Oncology will present updated Phase 1b data for LYT-200, an anti‑galectin‑9 antibody, at ASH on December 6, 2025. The ASH abstract reflects data as of July 8, 2025 with additional analyses expected at the meeting.
Data cover 31 monotherapy and 39 combination (LYT-200 + venetoclax/hypomethylating agents) participants dosed ≥7.5 mg/kg. Combination results include 12 CRs, 1 PR, 1 MLFS (CR rate >30% as of cut‑off). No dose‑limiting toxicities or LYT‑200‑related serious adverse events, discontinuations, or deaths were reported. Topline efficacy data expected Q4 2025; topline survival data expected H1 2026.
PureTech (Nasdaq: PRTC) announced new Phase 2b ELEVATE IPF sub-analyses presented at CHEST 2025 on October 22, 2025 showing deupirfenidone maintained a consistent safety and efficacy profile in patients aged ≥75 years versus <75 years.
The analysis compared deupirfenidone 825 mg TID and 550 mg TID to placebo and pirfenidone 801 mg TID, reporting similar treatment-emergent adverse events across age groups (subgroups: n=91 for ≥75; n=166 for <75) and comparable nausea rates across doses.
PureTech (NASDAQ:PRTC) announced promising new data from its Phase 2b open-label extension study of deupirfenidone (LYT-100) for idiopathic pulmonary fibrosis (IPF). The study demonstrated that patients switching from placebo or pirfenidone to deupirfenidone achieved lung function stabilization with favorable tolerability.
Key findings include patients switching from placebo to deupirfenidone showing a mean FVC change of +20.0 mL, while those switching from pirfenidone showed -23.1 mL. The drug maintained its efficacy over 52 weeks, with an overall FVC decline of -32.8 mL, comparable to natural decline in healthy older adults. The treatment was well-tolerated, with common side effects including nausea, dyspepsia, upper respiratory infections, and cough.
PureTech is currently engaging with regulators and expects to provide an update on Phase 3 trial design in Q4 2025.
PureTech's (NASDAQ: PRTC) Founded Entity, Seaport Therapeutics, has initiated a Phase 1 clinical trial of GlyphAgo™ (SPT-320), marking its second therapeutic candidate to enter clinical development. GlyphAgo is an oral prodrug of agomelatine designed to treat Generalized Anxiety Disorder (GAD).
The novel drug aims to overcome agomelatine's key limitation of first-pass liver metabolism by utilizing Seaport's proprietary Glyph™ platform to shift absorption toward intestinal lymphatics. Preclinical studies showed over 50% lymphatic transport and 10-fold increased plasma exposure compared to agomelatine alone.
The Phase 1 study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers, with the goal of achieving therapeutic levels at lower doses while reducing liver exposure.
PureTech Health (NASDAQ/LSE: PRTC) released its H1 2025 results, highlighting strong financial position with $319.6M in PureTech-level cash and operational runway into 2028. The company announced strategic refinements to its hub-and-spoke biotherapeutics model, focusing on capital-efficient development of high-potential programs.
Key developments include the launch of Celea Therapeutics to advance deupirfenidone, with Phase 3 trial initiation planned for H1 2026, and continued progress in Gallop Oncology's Phase 1b trial. The company maintains significant interests in various Founded Entities and retains rights to milestone payments and royalties from Karuna's Cobenfy™ following its acquisition by Bristol Myers Squibb.
Under new interim leadership with Sharon Barber-Lui as Board Chair and Robert Lyne as CEO, PureTech is strengthening its UK market presence and plans to add two new directors with UK capital markets expertise.
PureTech Health (NASDAQ: PRTC) presented compelling Phase 2b ELEVATE IPF trial data for deupirfenidone in idiopathic pulmonary fibrosis (IPF) at the 2025 IPF Summit in Boston. The trial demonstrated that deupirfenidone 825 mg TID reduced lung function decline by 80.9% versus placebo, showing approximately 50% greater treatment effect than pirfenidone.
Key findings include sustained efficacy through 52 weeks in the open-label extension study, with patients experiencing only a -32.8 mL decline in FVC, similar to natural decline in healthy older adults. The company also revealed that 69% of IPF patients in preference studies favored treatments offering greater efficacy over improved tolerability.
PureTech's newly launched Founded Entity, Celea Therapeutics, will advance deupirfenidone into Phase 3 trials, positioning it as a potential new standard of care in IPF treatment.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) has scheduled the release of its half-yearly results for the period ending June 30, 2025, to be announced on Thursday, August 28, 2025. The company will host a presentation and conference call for analysts and shareholders at 9:00 AM EDT / 2:00 PM BST on the same day. Interested parties can access the presentation webcast through PureTech's investor relations website.
Vedanta Biosciences, a PureTech (NASDAQ: PRTC) Founded Entity, announced that its Phase 2 COLLECTiVE202 study of VE202 for ulcerative colitis (UC) treatment failed to meet its primary endpoint of endoscopic response. While the treatment was well-tolerated with no serious adverse events, the response rates were not statistically different from placebo.
The company will now focus on its lead program VE303, currently in Phase 3 trials for recurrent Clostridioides difficile infection (CDI). VE303 previously showed promising Phase 2 results with a 30.5% absolute risk reduction compared to placebo. The program has received Fast Track and Orphan Drug designations from the FDA. Additionally, Vedanta is advancing VE707 for preventing multidrug-resistant infections, with an IND submission planned for 2026.
FAQ
What is the current stock price of Puretech Health (PRTC)?
What is the market cap of Puretech Health (PRTC)?
